First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
News|Articles|June 7, 2004
Cosmetic firms getting nailed for chemical in varnish
Nail polish makers Estee lauder and Procter & Gamble reformulate nail polishes--take DBP pthalate out amid health concerns
Advertisement
Advertisement
Related to this article
The once daily tablet is expected to reach US patients in October 2026.
The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
Advertisement
Advertisement
Trending on Drug Topics
1
From Binder to Action: Making Infectious Disease Outbreak Plans Operational
2
Retatrutide Delivers 20.8% Weight Loss in Adults With Type 2 Diabetes
3
Diabetes Medication Adherence Lags for Black and Hispanic Medicare Patients
4
Independent Pharmacies Remain Resilient, Essential Community Providers | NCPA 2026
5